

Date: 25<sup>th</sup> February, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001  
**BSE Scrip Code: 544179**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051  
**NSE Symbol: GODIGIT**

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of the acquisition/investment made by the Company on 25<sup>th</sup> February 2025 are enclosed herewith as an **Annexure 1** in accordance with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024.

We request you to kindly take the above intimation on record.

Thanking you,

Yours faithfully,

For **Go Digit General Insurance Limited**

**Tejas Saraf**  
**Company Secretary & Compliance Officer**

**Annexure 1**

**Details pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024:**

Sr. No.	Particulars	Details								
a	Name of the target entity, details in brief such as size, turnover etc.;	<p>Name: Dr. Reddy’s Laboratories Ltd (“Investee Company”)</p> <p>Market Cap (NSE/BSE): ₹ 94,137/94,221 crores (as on 25<sup>th</sup> February, 2025)</p> <p>History of Turnover (source: Annual Report)</p> <table border="1"> <thead> <tr> <th>Financial Year</th> <th>Amount (₹ in crores)</th> </tr> </thead> <tbody> <tr> <td>2023-24</td> <td>28,011</td> </tr> <tr> <td>2022-23</td> <td>24,670</td> </tr> <tr> <td>2021-22</td> <td>21,545</td> </tr> </tbody> </table>	Financial Year	Amount (₹ in crores)	2023-24	28,011	2022-23	24,670	2021-22	21,545
Financial Year	Amount (₹ in crores)									
2023-24	28,011									
2022-23	24,670									
2021-22	21,545									
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>Investment in Investee Company is not a related party transaction.</p> <p>Company’s promoter/promoter group/ group entities may have investment and other business related transaction/ arrangement with the Investee Company at arm’s length.</p>								
c	Industry to which the entity being acquired belongs	Pharmaceuticals								
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment in shares is being made in the ordinary course of investment function of the Company.								
e	Brief details of any governmental or regulatory approvals required for the acquisition	None								
f	Indicative time period for completion of the acquisition	The Company has invested in the shares of the Investee Company on 25 <sup>th</sup> February, 2025.								
g	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration								
h	Cost of acquisition and/or the price at which the shares are acquired	The Company has made an investment of Rs. 30.06 crores in the shares of the Investee Company.								

i	<b>Percentage of shareholding / control acquired and / or number of shares acquired</b>	Post this investment on 25 <sup>th</sup> February, 2025, the cumulative holding of the Company in the Investee Company is 0.32%.								
j	<b>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</b>	<p>Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.</p> <p>The Investee Company was incorporated on 24<sup>th</sup> February 1984</p> <p>History of Turnover (Annual Report)</p> <table border="1" data-bbox="794 891 1407 1059"> <thead> <tr> <th>Financial Year</th> <th>Amount (₹ in crores)</th> </tr> </thead> <tbody> <tr> <td>2023-24</td> <td>28,011</td> </tr> <tr> <td>2022-23</td> <td>24,670</td> </tr> <tr> <td>2021-22</td> <td>21,545</td> </tr> </tbody> </table> <p>Country of Presence/Registration: India</p>	Financial Year	Amount (₹ in crores)	2023-24	28,011	2022-23	24,670	2021-22	21,545
Financial Year	Amount (₹ in crores)									
2023-24	28,011									
2022-23	24,670									
2021-22	21,545									